Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02950051
Brief Title: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (GAIA)

First Submitted : October 27, 2016
First Submitted that Met QC Criteria : October 27, 2016
First Posted : October 31, 2016 (Estimate)

Last Update Submitted that Met QC Criteria : July 30, 2019
Last Update Posted : August 1, 2019